Clinical trials
Phase 4 Schizophrenia trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
30 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 4 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 4 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 3 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 24 |
| Terminated | 4 |
| Recruiting | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Heinrich-Heine University, Duesseldorf | 4 |
| AstraZeneca | 3 |
| Central Institute of Mental Health, Mannheim | 3 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 |
| Bristol-Myers Squibb | 1 |
| Charite University, Berlin, Germany | 1 |
| Dr. Inge Winter | 1 |
| Eli Lilly and Company | 1 |
| Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH | 1 |
| Janssen-Cilag G.m.b.H | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Schizophrenia | 30 |
| Psychotic Disorders | 12 |
| Autistic Disorder | 1 |
| Bipolar Disorder | 1 |
| Metabolic Syndrome | 1 |
| Prodromal Symptoms | 1 |
| Schizophrenia Spectrum and Other Psychotic Disorders | 1 |
| Schizophrenia, Paranoid | 1 |
| Weight Gain | 1 |
Trials
Showing 1 to 25 of 30. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.